ClinicalTrials.gg
RecruitingNCT05390047iSuSIUpdated Jul 1, 2024

The International SubcutaneouS Implantable Cardioverter Defibrillator Registry (iSuSI)

An observational study in Sudden Cardiac Death, sponsored by University of Luebeck. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by University of Luebeck · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
4,000
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Death, Sudden, Cardiac with a site in Germany — 6 open to participants now, 7 under way, none of them phase 3. Death, Sudden, Cardiac · Germany.

Planned enrollment
2nd of 24
4,000 · median 410
Started
2022
the only one that year
Observational
24 of 43
3 open now
Registered
39th of 43
by date

Among the 43 studies in Death, Sudden, Cardiac with a site in Germany, this one is the 2nd largest by planned enrollment of the 24 observational ones that give a count, is the only one that started in 2022, is one of 24 observational ones, and was the 39th registered.

Death, Sudden, Cardiac

364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.

Browse Death, Sudden, Cardiac studies →

Open to participants now

6 of the 43 studies in Death, Sudden, Cardiac with a site in Germany are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Death, Sudden, Cardiac with a site in Germany, or all of them as a file.
02

Study summary

The entirely subcutaneous implantable defibrillator (S-ICD) (Emblem, Boston Scientific, Marlborough, MA, USA) was introduced as a new therapeutic alternative to the conventional transvenous ICD in 2009 and implantations are rapidly expanding since then.1 Implantation of the S-ICD seems to reduce implant-related perioperative complications such as pneumothorax, hematoma and cardiac tamponade.

The aim of this multicenter registry is thus to assess the outcome of patients following an S-ICD implantation in a real-world setting.

Read the detailed description

The S-ICD has a CE mark and is FDA approved since 2012 and is mentioned as a potential therapy strategy in the current AHA guidelines on the management of patients with ventricular arrhythmias.2 However, although implant-related complications seem to be reduced by the S-ICD in randomized controlled trials, the rate of inappropriate shocks remains high in S-ICD patients (10-13%).3-5 The most common reason for inappropriate shocks is cardiac oversensing, mostly due to T-wave oversensing or low amplitude of the subcutaneous signal, which not commonly found in patients with transvenous ICDs. Data on the role of the Defibrillation Threshold Testing (DFT), the rate of infectious complications (lead or device complications), the use of the S-ICD in children and adolescents, and the outcome of patients with an S-ICD according to their underlying cardiac substrate are sparse. The aim of this multicenter registry is thus to assess the outcome of patients following an S-ICD implantation in a real-world setting with a special focus on perioperative complication rate, the role of DFT testing in S-ICD, the use of the S-ICD in cohorts that are underrepresented in clinical studies (adolescents and geriatrics), the outcome and risk factors of ineffective, inappropriate and appropriate shocks and the differences in outcomes according to the underlying cardiac disease.

03

Conditions studied

  • Sudden Cardiac Death

Keywords

  • subcutaneous implantable cardioverter defibrillator
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients in whom a S-ICD was implanted for primary or secondary prevention

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Implantation of an S-ICD, regardless of the technique
  • At least 1 month of follow up
  • At least 1 post-implantation assessment, in accordance to the routine clinical practice of every center (e.g. in person visit or remote follow up)

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
4,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Overall complication rate

    combination of device related complications and inappropriate shocks

    Time frame: through study completion, an average of 2 years

  2. Rate of appropriate shocks

    Appropriate therapies delivered by the devices

    Time frame: through study completion, an average of 2 years

  3. Rate of inappropriate shocks

    Inappropriate therapies delivered by the devices

    Time frame: through study completion, an average of 2 years

Secondary outcomes

  1. Device-related complication rate

    Rate of complications pertaining to the device

    Time frame: immediately after the intervention/procedure/surgery"

  2. DFT impact

    Impact of defibrillator function test (DFT) on long term arrhythmia outcome or mortality

    Time frame: 2 year

  3. Rate of replacements

    Generator replacements

    Time frame: 2 year

  4. Role of Gender in primary outcomes

    Analysis of the potential role of gender on the primary outcomes

    Time frame: through study completion, an average of 2 year

  5. Rate of device upgrades

    need for device upgrade due to pacing needs

    Time frame: through study completion, an average of 2 year

07

Study locations

1 of 1 sites recruiting
  • Clinic for Rhythmology
    Luebeck, Schleswig Holstein 23538, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Jun 2025, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
May 25, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Jun 1, 2025
CompletionEst.
Sep 30, 2025
Last update
Jul 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05390047
Lead sponsor
University of Luebeck
Collaborators
Prof. Jürgen Kuschyk, M.D, Giovanni Forleo, M.D., Mauro Biffi, M.D.
Responsible party
Prof. Roland Richard Tilz (Prof. Dr. med. Roland Richard Tilz, University of Luebeck) — Principal investigator
First posted
May 25, 2022
Start date
Jul 1, 2022
Primary completion
Jun 1, 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Jul 1, 2024

Study contacts

Julia Vogler, Dr.
Contact
Julia.vogler@uksh.de
+49 451 500 ext. 44639
Cornelia Wolf
Contact
cornelia.wolf@uksh.de
+49451500 ext. 44540

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion